CinQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo

Carcinogenesis

Volumn 34, Issue 5, 2013, Pages 1134-1143

  Kim, Dong Joon ^a,b   Lee, Mee Hyun ^a   Reddy, Kanamata ^a   Li, Yani ^a   Lim, Do Young ^a   Xie, Hua ^a   Lee, Sung Young ^a   Yeom, Young Il ^b   Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CINQ 01; CINQ 03; CINQ 06; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ALLOSTERIC REGULATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; TRANSCRIPTION FACTOR AP-1;

EID: 84877151489     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt015     Document Type: Article

References (38)

1. Schubbert,S. et al. (2007) Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer, 7, 295-308.
2. Sjöblom,T. et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science, 314, 268-274.
3. Pearson,G. et al. (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr. Rev., 22, 153-183.
4. Anjum,R. et al. (2008) The RSK family of kinases: emerging roles in cellular signalling. Nat. Rev. Mol. Cell Biol., 9, 747-758.
5. Eisinger-Mathason,T.S. et al. (2010) RSK in tumorigenesis: connections to steroid signaling. Steroids, 75, 191-202.
6. Cowley,S. et al. (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell, 77, 841-852.
7. Mansour,S.J. et al. (1994) Transformation of mammalian cells by constitutively active MAP kinase kinase. Science, 265, 966-970.
8. Shields,J.M. et al. (2000) Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol., 10, 147-154.
9. Estep,A.L. et al. (2007) Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE, 2, e1279.
10. Kim,D.J. et al. (2012) Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Cancer Res., 72, 3060-3068.
11. Zhu,F. et al. (2007) Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology, 133, 219-231.
12. McCubrey,J.A. et al. (2010) Emerging MEK inhibitors. Expert Opin. Emerg. Drugs, 15, 203-223.
13. Liu,X. et al. (2004) The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene, 23, 763-776.
14. Zheng,C.F. et al. (1993) Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2. J. Biol. Chem., 268, 11435-11439.
15. Bélanger,L.F. et al. (2003) Mek2 is dispensable for mouse growth and development. Mol. Cell. Biol., 23, 4778-4787.
16. Giroux,S. et al. (1999) Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol., 9, 369-372.
17. Davies,B.R. et al. (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol. Cancer Ther., 6, 2209-2219.
18. Lorusso,P.M. et al. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J. Clin. Oncol., 23, 5281-5293.
19. Menon,U. et al. (2005) Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J. Clin. Oncol., 23, 7919-7926.
20. Dudley,D.T. et al. (1995) A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. U.S.A., 92, 7686-7689.
21. Favata,M.F. et al. (1998) Identification of a novel inhibitor of mitogenactivated protein kinase kinase. J. Biol. Chem., 273, 18623-18632.
22. Sebolt-Leopold,J.S. et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 5, 810-816.
23. Solit,D.B. et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature, 439, 358-362.
24. Adjei,A.A. et al. (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol., 26, 2139-2146.
25. Huynh,H. et al. (2007) Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol. Cancer Ther., 6, 138-146.
26. Yeh,T.C. et al. (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res., 13, 1576-1583.
27. Messersmith,W.A. et al. (2006) Novel targets in solid tumors: MEK inhibitors. Clin. Adv. Hematol. Oncol., 4, 831-836.
28. Schad,K. et al. (2010) Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin. Cancer Res., 16, 1058-1064.
29. Balagula,Y. et al. (2011) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest. New Drugs, 29, 1114-1121.
30. Ohren,J.F. et al. (2004) Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat. Struct. Mol. Biol., 11, 1192-1197.
31. Friesner,R.A. et al. (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 49, 6177-6196.
32. Daouti,S. et al. (2009) Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy. Cancer Res., 69, 1924-1932.
33. Iverson,C. et al. (2009) RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res., 69, 6839-6847.
34. Yang,J.Y. et al. (2010) Activation of FOXO3a is sufficient to reverse mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor chemoresistance in human cancer. Cancer Res., 70, 4709-4718.
35. Wang,D. et al. (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim. Biophys. Acta, 1773, 1248-1255.
36. Wang,J.Y. et al. (2007) Recent advances of MEK inhibitors and their clinical progress. Curr. Top. Med. Chem., 7, 1364-1378.
37. Dumesic,P.A. et al. (2009) Erk1/2 MAP kinases are required for epidermal G2/M progression. J. Cell Biol., 185, 409-422.
38. Scholl,F.A. et al. (2009) Mek1/2 gene dosage determines tissue response to oncogenic Ras signaling in the skin. Oncogene, 28, 1485-1495.